2-羟基-2,4,4-三甲基-3-戊酮 | 546-95-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-羟基-2,4,4-三甲基-3-戊酮
• 英文名称: 2-hydroxy-2,4,4-trimethylpentan-3-one
• 英文别名: 2-hydroxy-2,4,4-trimethyl-3-pentanone；2-Hydroxy-2,4,4-trimethyl-pentan-3-on；2.2.4-Trimethyl-pentanol-(4)-on-(3)；Dimethyl-pivaloyl-carbinol；Oxoctenol
• CAS: 546-95-2
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: OZYZMDZCGQDZQN-UHFFFAOYSA-N

物化性质

• 熔点：
  50.4-51.8 °C
• 沸点：
  185-187 °C
• 密度：
  0.928±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-羟基-2,4,4-三甲基-3-戊酮 在 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成 Methanesulfonic acid 1,1,3,3-tetramethyl-2-oxo-butyl ester
  参考文献：
  名称：

  Competing kc, borderline, ks, and carbonyl addition processes in solvolyses of .alpha.-keto mesylates and triflates. .alpha.-Keto cations. 5

  摘要：

  DOI：

  10.1021/ja00331a029
• 作为产物：
  描述：

  2,3-环氧-2,4,4-三甲基戊烷 在 [双(三氟乙酰氧基)碘]苯 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以60%的产率得到2-羟基-2,4,4-三甲基-3-戊酮
  参考文献：
  名称：

  Ring opening of oxiranes by I,I-bis(trifluoroacetoxy)iodobenzene

  摘要：

  DOI：

  10.1021/jo00338a041

文献信息

• NOVEL INHIBITORS OF HEPATITIS C VIRUS
  申请人：McKINNELL Robert Murray

  公开号：US20120114600A1

  公开（公告）日：2012-05-10

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  该发明提供了以下式(I)的化合物： 其中变量在规范中定义，或其药用可接受盐，这些化合物是乙型肝炎病毒复制的抑制剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及用于制备这些化合物的工艺和中间体。
• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。
• Design, Synthesis and Olfactory Properties of 2-Substituted 2-<i>tert</i>-Butyl-5-­methyl-2,5-dihydrofurans: <i>seco</i>-Derivatives of Theaspiranes
  作者：Philip Kraft、Kasim Popaj、Agnese Abate

  DOI：10.1055/s-2005-918404

  日期：——

  Two seco-theaspiranes with pronounced blackcurrant notes, 2-tert-butyl-5-methyl-2-propyl-2,5-dihydrofuran (7) and 2-tert-butyl-5-methyl-2-propyltetrahydrofuran (8), were synthesized by a synthetic sequence consisting of Grignard reaction, Lindlar ­hydrogenation, and cyclization followed by optional Pd-catalyzed hydrogenation. The sequence was modified for the synthesis of the oxygenated analogs 2-(2′-tert-butyl-5′-methyltetrahydrofuran-2′-yl)propan-2-ol (9) and 3-(2′-tert-butyl-5′-methyltetrahydrofuran-2′-yl)butan-2-one (10). The first modification featured trimethyl­silyl ether protection and stepwise construction of the alkyne moiety necessitated by steric hindrance. In the second modification, a but-2-en-2-yl group was utilized as latent 3-hydroxybut-1-en-2-yl functionality, and the steric constraint around the tertiary hydroxy group was exploited to introduce a stereocenter by SN2 ring closure. As for the parent compounds 7 and 9, the odor of the oxygenated seco-­theaspiranes was shifted towards a woody tonality. The like-diastereo­mer 9a even had a typical patchouli profile, and the ­enantiomers 10a and 10b differed significantly in their olfactory properties.

  具有明显黑加仑香味的两种次级锡兰螺环烷，2-叔丁基-5-甲基-2-丙基-2,5-二氢呋喃（7）和2-叔丁基-5-甲基-2-丙基四氢呋喃（8），通过包括格氏反应、林德拉氢化和环化，随后可选择钯催化的氢化反应的合成序列合成。该序列经过修改，用于合成含氧化合物2-(2'-叔丁基-5'-甲基四氢呋喃-2'-基)丙烷-2-醇（9）和3-(2'-叔丁基-5'-甲基四氢呋喃-2'-基)丁烷-2-酮（10）。第一次修改特色是三甲基硅醚保护以及由于空间位阻所需的乙炔部分的逐步构建。在第二次修改中，使用2-丁烯-2-基作为潜在的3-羟基丁烯-1-烯-2-基功能性，并通过SN2环闭合引入立体中心，利用围绕三级羟基的空间约束。至于母体化合物7和9，含氧次级锡兰螺环烷的香味向木质调性转变。相似的非对映异构体9a甚至具有典型的广藿香特征，而其对映体10a和10b在嗅觉特性上有显著差异。
• Substituted Azaspiro(4.5)Decane Derivatives
  申请人：Gruenenthal GmbH

  公开号：US20160016903A1

  公开（公告）日：2016-01-21

  The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

  这项发明涉及对取代的螺环烷环己烷衍生物，其具有对μ阿片受体和ORL1受体的亲和力，以及其制备方法、含有这些化合物的药物和利用这些化合物制备药物的用途。
• COFLUORONS AND METHODS OF MAKING AND USING THEM
  申请人：Barany Francis

  公开号：US20140161729A1

  公开（公告）日：2014-06-12

  The present invention is directed to method of using a collection of monomers capable of forming multimers as a fluorescence reporter in different applications such as ligand detection/screening, disease diagnosis, drug discovery or screening, fluorescent labeling and imaging, or other fluorescent methodologies. Each monomer in the collection includes one or more ligand elements useful for binding to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the ligand elements directly or indirectly through a connector. Association of linker elements of different combinations of monomers, with their ligand elements bound to the target molecule to form a multimer, will generate a unique fluorescent signature different from that produced by those monomers either alone or in association with each other in the absence of the target molecule, when subjected to electromagnetic excitement.

  本发明涉及使用一组能够形成多聚体的单体作为荧光报告物在不同应用中的方法，例如配体检测/筛选、疾病诊断、药物发现或筛选、荧光标记和成像，或其他荧光方法学。该组合中的每个单体均包括一个或多个配体元素，用于与解离常数小于300μM的靶分子结合，并且连接到配体元素的连接器通过直接或间接连接到配体元素。不同单体组合的连接器元素与其配体元素结合到靶分子形成多聚体，将产生一种独特的荧光特征，与那些单体单独或在没有靶分子的情况下相互结合时产生的荧光特征不同，当受到电磁激发时。